S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ANIP · ANI Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
ANI Pharmaceuticals Inc (ANIP)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$72.28
-0.34
(-0.48%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$72.28
$71.92
$73.30
52-WEEK RANGE
$72.28
$69.58
$97.00
What's happening
- ANIP is down 0.48% today, trading at $72.28. — Live quote
- Volume today (16,136) is well below its 3-month average of 364,530. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $2.21 actual vs. $2.09 estimated (+5.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 7
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ANIP
-8.49%
vs S&P 500
-21.86%
1-YEAR RETURN
ANIP
-24.26%
vs S&P 500
-39.43%
6-MONTH RETURN
ANIP
-10.73%
3-MONTH RETURN
ANIP
-6.92%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$2.21
Est. $2.09
BEAT +5.7%
2026-04-26 (Q1 2026)
$2.05
Est. $1.33
BEAT +54.0%
2026-01-26 (Q4 2025)
$2.33
Est. $2.04
BEAT +14.5%
2025-10-26 (Q3 2025)
$2.04
Est. $1.79
BEAT +14.0%
Valuation Measures & Ratios
Enterprise Value4$1.92B
Forward P/E57.73
PEG Ratio61.09
Price / Sales (TTM1)1.71
Price / Book73.15
EV4 / Revenue1.97
EV4 / EBITDA8.15
Profit Margin11.07%
Operating Margin15.37%
Return on Equity (ROE8)19.64%
Return on Assets (ROA9)7.52%
Avg Volume (3M)364,530
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.95B | $1.77B | $2.16B | $1.55B | $1.52B |
| P/E | 21.82 | 22.05 | 81.01 | -696.61 | 204.73 |
| Price/Sales | 2.07 | 2.03 | 2.75 | 2.23 | 2.45 |
| Price/Book | 3.26 | 3.15 | 4.27 | 3.55 | 3.64 |
| EV/Revenue | 2.01 | 2.02 | 2.82 | 2.37 | 2.72 |
| ROE | 14.96% | 14.29% | 5.27% | -0.51% | 1.78% |
| ROA | 5.98% | 5.65% | 1.89% | -0.17% | 0.58% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,491,281
Change from Prior Settlement+40.20%
% of Float—
Days to Cover (Short Ratio)7.16
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 25.9% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 11.1%. Finnhub fundamentals ↗
Potential concerns
- Trailing 52-week price return is -24.3%. Finnhub market metrics ↗
- Latest SEC filing is Form 4, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ANIP
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $266.0M | $237.5M | $227.8M | $211.4M | $197.1M | $148.3M | $138.0M | $137.4M |
| Operating income | $40.5M | $38.9M | $36.2M | $13.9M | $26.2M | -$20.5M | $5.2M | $20.3M |
| Net income | $24.7M | $29.5M | $26.6M | $8.5M | $15.7M | -$24.2M | -$2.3M | $18.2M |
| EPS (diluted) | $1.05 | $1.28 | $1.13 | $0.36 | $0.69 | $-1.27 | $-0.14 | $0.82 |
| EPS (basic) | $1.09 | $1.31 | $1.19 | $0.37 | $0.70 | $-1.27 | $-0.14 | $0.84 |
| Operating margin | $15 | $16 | $16 | $7 | $13 | -$14 | $4 | $15 |
| Net margin | $9 | $12 | $12 | $4 | $8 | -$16 | -$2 | $13 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.49B | $1.42B | $1.44B | $1.41B | $1.34B | $1.29B | $1.28B | $1.29B |
| Total liabilities | $896.9M | $859.7M | $899.7M | $902.3M | $881.4M | $849.0M | $855.9M | $856.6M |
| Stockholders' equity | $597.2M | $562.3M | $540.7M | $505.8M | $436.8M | $418.6M | $403.7M | $405.9M |
| Total current assets | $825.4M | $747.1M | $753.1M | $698.4M | $602.6M | $536.3M | $528.5M | $521.3M |
| Total current liabilities | $283.7M | $239.5M | $278.1M | $270.6M | $236.8M | $201.8M | $194.5M | $189.9M |
| Cash & equivalents | $360.2M | $311.2M | $285.6M | $262.6M | $217.8M | $149.8M | $144.9M | $145.0M |
| Accounts receivable | $274.5M | $255.4M | $281.1M | $252.6M | $225.7M | $220.3M | $221.7M | $196.4M |
| Inventory | $143.1M | $143.5M | $143.1M | $146.5M | $138.3M | $137.4M | $136.8M | $148.0M |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $73.2M | $67.1M | $62.5M | $63.6M | $59.2M | $58.2M | $56.9M | $56.7M |
| Goodwill | $62.5M | $62.5M | $62.5M | $62.5M | $60.5M | $60.7M | $60.0M | $60.4M |
| Intangible assets | $449.9M | $467.2M | $479.5M | $499.8M | $520.3M | $538.5M | $541.8M | $569.8M |
| Other non-current assets | $11.6M | $11.6M | $13.7M | $12.5M | $8.2M | $10.3M | $12.2M | $11.5M |
| Accounts payable | $73.8M | $69.7M | $62.6M | $69.8M | $54.6M | $53.1M | $45.7M | $60.9M |
| Accrued liabilities | $16.6M | $13.7M | $17.0M | $14.0M | $14.8M | $12.0M | $13.7M | $17.8M |
| Deferred revenue (current) | — | — | — | — | — | — | — | $5.0M |
| Short-term debt | $21.3M | $19.3M | $17.3M | $15.2M | $13.2M | $11.2M | $9.2M | $7.2M |
| Long-term debt | $280.2M | $286.0M | $291.8M | $297.7M | $301.5M | $305.3M | $309.1M | $312.9M |
| Other non-current liabilities | $15.5M | $16.4M | $12.2M | $11.3M | $6.7M | $7.0M | $5.8M | $6.9M |
| Common stock & paid-in capital | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | $2.0K | $2.0K |
| Retained earnings | $31.1M | $6.4M | -$23.1M | -$50.6M | -$76.9M | -$85.0M | -$100.3M | -$89.6M |
| Accumulated other comprehensive income (loss) | -$327.0K | $479.0K | $1.0M | $2.8M | $3.3M | $3.6M | $5.3M | $5.4M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $56.7M | $58.4M | $30.4M | $44.1M | $75.8M | $35.0M | $15.9M | $12.5M |
| Investing cash flow | -$3.1M | -$11.3M | -$1.4M | -$6.2M | -$6.9M | -$19.8M | -$10.7M | -$398.5M |
| Financing cash flow | -$4.6M | -$21.6M | -$4.6M | $6.3M | -$1.7M | -$9.9M | -$4.9M | $291.0M |
| Free cash flow | $53.6M | $52.3M | $29.1M | $38.0M | $71.8M | $32.5M | $13.5M | $7.7M |
| Capital expenditures | $3.1M | $6.1M | $1.2M | $6.1M | $4.0M | $2.5M | $2.4M | $4.8M |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $11.4M | $10.2M | $9.8M | $9.7M | $9.6M | $8.9M | $7.1M | $7.5M |
| Deferred income taxes | — | — | $11.8M | — | — | — | -$23.0M | — |
| Change in accounts receivable | $19.1M | -$25.5M | $27.9M | $27.0M | $5.5M | -$1.8M | $25.5M | -$8.4M |
| Change in inventory | -$305.0K | $437.0K | -$3.7M | $8.2M | $908.0K | $625.0K | $675.0K | $6.4M |
| Change in accounts payable | -$1.1M | $5.4M | -$7.2M | $13.8M | $3.1M | $5.5M | -$6.8M | -$3.1M |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Dividends paid | $0 | $0 | $0 | $344.0K | $407.0K | $406.0K | $406.0K | $406.0K |
| Share repurchases | $813.0K | $19.8M | $611.0K | $1.0M | $551.0K | $10.0M | $318.0K | $680.0K |
| Debt issued | — | — | — | — | — | — | — | — |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $883.4M | $614.4M | $486.8M | $316.4M | $216.1M |
| Operating income | $111.1M | $584.0K | $47.0M | -$35.3M | -$39.8M |
| Net income | $78.3M | -$18.5M | $18.8M | -$47.9M | -$42.6M |
| EPS (diluted) | $3.32 | $-1.04 | $0.85 | $-3.05 | $-3.40 |
| EPS (basic) | $3.50 | $-1.04 | $0.86 | $-3.05 | $-3.40 |
| Operating margin | $13 | $0 | $10 | -$11 | -$18 |
| Net margin | $9 | -$3 | $4 | -$15 | -$20 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $1.44B | $1.28B | $904.4M | $760.1M | $771.6M |
| Total liabilities | $899.7M | $855.9M | $446.8M | $421.5M | $412.9M |
| Stockholders' equity | $540.7M | $403.7M | $432.7M | $313.7M | $333.9M |
| Total current assets | $753.1M | $528.5M | $519.8M | $344.3M | $321.8M |
| Total current liabilities | $278.1M | $194.5M | $145.5M | $99.4M | $87.5M |
| Cash & equivalents | $285.6M | $144.9M | $221.1M | $48.2M | $100.3M |
| Accounts receivable | $281.1M | $221.7M | $162.1M | $165.4M | $128.5M |
| Inventory | $143.1M | $136.8M | $111.2M | $105.4M | $81.7M |
| Marketable securities (non-current) | — | — | — | — | — |
| Property, plant & equipment | $62.5M | $56.9M | $44.6M | $43.2M | $52.7M |
| Goodwill | $62.5M | $60.0M | $28.2M | $28.2M | $27.9M |
| Intangible assets | $479.5M | $541.8M | $209.0M | $251.6M | $294.1M |
| Other non-current assets | $13.7M | $12.2M | $12.1M | $11.4M | $2.2M |
| Accounts payable | $62.6M | $45.7M | $36.7M | $29.3M | $23.0M |
| Accrued liabilities | $16.8M | $13.7M | $5.6M | $5.4M | $7.7M |
| Deferred revenue (current) | — | — | — | $0 | $100.0K |
| Short-term debt | $17.3M | $9.2M | $850.0K | $850.0K | $850.0K |
| Long-term debt | $291.8M | $309.1M | $284.8M | $285.7M | $286.5M |
| Other non-current liabilities | $12.2M | $5.8M | $4.8M | $1.4M | $7.8M |
| Common stock & paid-in capital | $3.0K | $2.0K | $2.0K | $1.0K | $1.0K |
| Retained earnings | -$23.1M | -$100.3M | -$80.1M | -$97.3M | -$47.8M |
| Accumulated other comprehensive income (loss) | $1.0M | $5.3M | $8.9M | $12.2M | -$3.1M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $185.2M | $64.0M | $119.0M | -$31.2M | $3.3M |
| Investing cash flow | -$34.3M | -$404.7M | -$18.5M | -$15.7M | -$105.5M |
| Financing cash flow | -$9.9M | $264.9M | $67.4M | -$5.1M | $194.6M |
| Free cash flow | $171.4M | $47.8M | $110.1M | -$40.1M | $765.0K |
| Capital expenditures | $13.8M | $16.2M | $8.9M | $8.9M | $2.6M |
| Depreciation & amortization | — | — | — | — | $47.3M |
| Share-based compensation | $37.9M | $29.3M | $20.7M | $14.6M | $10.5M |
| Deferred income taxes | $11.8M | -$23.0M | -$11.6M | -$15.2M | -$16.9M |
| Change in accounts receivable | $58.5M | $21.1M | -$3.4M | $36.9M | $5.5M |
| Change in inventory | $6.0M | $21.3M | $5.8M | $23.6M | -$3.2M |
| Change in accounts payable | $15.2M | $479.0K | $7.6M | $5.0M | $10.2M |
| Purchases of investments | — | — | — | — | — |
| Dividends paid | $1.2M | $1.6M | $1.6M | $1.6M | $190.0K |
| Share repurchases | $12.2M | $11.0M | $5.0M | $2.0M | $890.0K |
| Debt issued | — | — | — | — | — |
| Other financing activities | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ANIP as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-05-11 to 2026-10-15
Recent transactions
- Insiders have net sold 57,319 shares over the last 182 days, across 0 purchases and 20 sales.
- Most recent: Lalwani Nikhil (PRESIDENT & CEO) — Open market sale of 5,400 shares on 2026-10-15.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)57,319 sh(20 txns)
Net Shares-57,319
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Lalwani Nikhil | PRESIDENT & CEO | Open market sale | 2026-10-15 | 5,400 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Open market sale | 2026-10-13 | 500 |
| CAREY STEPHEN P. | SVP & CFO | Open market sale | 2026-09-29 | 2,850 |
| Thoma Jeanne | Director | Open market sale | 2026-09-11 | 1,000 |
| Gosebruch Henry O | Director | Grant / award | 2026-08-19 | 6,662 |
| Gutwerg Ori | SVP, GENERICS | Open market sale | 2026-08-10 | 3,162 |
| HAUGHEY THOMAS | Director | Open market sale | 2026-06-08 | 2,000 |
| TANNENBAUM RENEE P | Director | Grant / award | 2026-05-21 | 4,357 |
| Pera Antonio R | Director | Grant / award | 2026-05-21 | 4,357 |
| Leonard Matthew J | Director | Grant / award | 2026-05-21 | 4,357 |
| Walsh Patrick D | Director | Open market sale | 2026-05-13 | 10,000 |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Open market sale | 2026-05-12 | 459 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-15 | Lalwani Nikhil | PRESIDENT & CEO | Open market sale | 5,400 | $71.89 |
| 2026-10-13 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Open market sale | 500 | $73.59 |
| 2026-09-29 | CAREY STEPHEN P. | SVP & CFO | Open market sale | 2,850 | $73.00 |
| 2026-09-15 | Lalwani Nikhil | PRESIDENT & CEO | Open market sale | 5,400 | $71.00 |
| 2026-09-14 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Open market sale | 500 | $70.79 |
| 2026-09-11 | Thoma Jeanne | Director | Open market sale | 1,000 | $71.53 |
| 2026-08-31 | CAREY STEPHEN P. | SVP & CFO | Open market sale | 2,850 | $72.80 |
| 2026-08-25 | Lalwani Nikhil | PRESIDENT & CEO | Open market sale | 5,400 | $74.30 |
| 2026-08-19 | Gosebruch Henry O | Director | Grant / award | 6,662 | $0.00 |
| 2026-08-13 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Open market sale | 500 | $75.48 |
| 2026-08-10 | Gutwerg Ori | SVP, GENERICS | Open market sale | 3,162 | $77.00 |
| 2026-07-29 | CAREY STEPHEN P. | SVP & CFO | Open market sale | 2,850 | $81.36 |
| 2026-07-18 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Tax withholding | 2,466 | $79.20 |
| 2026-07-13 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Open market sale | 500 | $81.84 |
| 2026-07-02 | CAREY STEPHEN P. | SVP & CFO | Option exercise | 3,313 | $49.51 |
| 2026-07-02 | CAREY STEPHEN P. | SVP & CFO | Open market sale | 3,313 | $86.00 |
| 2026-06-29 | CAREY STEPHEN P. | SVP & CFO | Open market sale | 2,850 | $84.12 |
| 2026-06-12 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Open market sale | 500 | $82.03 |
| 2026-06-08 | HAUGHEY THOMAS | Director | Open market sale | 2,000 | $80.88 |
| 2026-06-05 | CAREY STEPHEN P. | SVP & CFO | Option exercise | 3,312 | $49.51 |
| 2026-06-05 | CAREY STEPHEN P. | SVP & CFO | Open market sale | 3,312 | $80.00 |
| 2026-05-21 | Thoma Jeanne | Director | Grant / award | 4,357 | $0.00 |
| 2026-05-21 | TANNENBAUM RENEE P | Director | Grant / award | 4,357 | $0.00 |
| 2026-05-21 | Pera Antonio R | Director | Grant / award | 4,357 | $0.00 |
| 2026-05-21 | Leonard Matthew J | Director | Grant / award | 4,357 | $0.00 |
| 2026-05-21 | HAUGHEY THOMAS | Director | Grant / award | 4,357 | $0.00 |
| 2026-05-13 | Walsh Patrick D | Director | Open market sale | 10,000 | $80.63 |
| 2026-05-12 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Open market sale | 459 | $79.21 |
| 2026-05-11 | Walsh Patrick D | Director | Open market sale | 3,973 | $80.75 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 4 | 2026-10-15 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-13 | View on SEC.gov → |
| 2026-09-30 | 4 | 2026-09-29 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-11 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-08-27 | 4 | 2026-08-19 | View on SEC.gov → |
| 2026-08-26 | 4 | 2026-08-25 | View on SEC.gov → |
| 2026-08-24 | 8-K | 2026-08-19 | View on SEC.gov → |
| 2026-08-13 | 4 | 2026-08-13 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-10 | View on SEC.gov → |
Recent news
Headlines about ANIP (ANI Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
Trading Systems Reacting to (ANIP) Volatility
Stock Traders Daily · 2026-10-20 -
ANI Pharmaceuticals, Inc. (ANIP) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
ANI Pharmaceuticals Launches Duloxetine Delayed-Release Capsules 20, 30 and 60 mg Generic to Cymbalta
Quiver Quantitative · 2026-10-19 -
ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules
Yahoo · 2026-10-19 -
ANI Pharmaceuticals Launches Duloxetine Delayed-Release Capsules 20, 30 And 60 Mg, Generic Version Of Reference Listed Drug Cymbalta
Benzinga · 2026-10-19 -
ANI Pharmaceuticals (ANIP) Holds Steady at $72.29 as Traders Eye Resistance - Aggressive Growth Picks
https://www.siam.in/ · 2026-10-17 -
ANI Pharmaceuticals (ANIP) Holds Steady at $72.29 as Traders Eye Resistance - Charm Flow
www.siam.in · 2026-10-17 -
ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Nikhil Lalwani Sells 5,400 Shares
MarketBeat · 2026-10-16
No headlines in this category right now — try “All”.